{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-225853","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.903570+00:00","generated_at":"2026-05-17T05:02:57.895388+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Halozyme to acquire Elektrofi for $750M upfront, expanding drug delivery offerings into 2040s","bullets":["Upfront payment $750M; up to three $50M milestones contingent on product regulatory approvals.","Hypercon technology enables 400-500 mg/ml concentrations, up to 4-5x standard aqueous formulations.","Two partner products expected to begin clinical development by year-end 2026 or earlier.","Royalty revenue expected to begin 2030; deal less than 5% dilutive to Non-GAAP EPS over medium term.","Halozyme reaffirms 2025 guidance: rev $1.275-1.355B, Adj EBITDA $865-915M, Non-GAAP EPS $6.00-6.40."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-225853","json":"https://secwatch.observer/filing/0001193125-25-225853.json","markdown":"https://secwatch.observer/filing/0001193125-25-225853.md","text":"https://secwatch.observer/filing/0001193125-25-225853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525225853/0001193125-25-225853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000119312525225853/d940775d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:02:57.895388+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}